These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29450984)

  • 1. Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations.
    Bai Q; Pérez-Sánchez H; Shi Z; Li L; Shi D; Liu H; Yao X
    Chem Biol Drug Des; 2018 Jul; 92(1):1221-1231. PubMed ID: 29450984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
    Yin J; Mobarec JC; Kolb P; Rosenbaum DM
    Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA.
    Suno R; Kimura KT; Nakane T; Yamashita K; Wang J; Fujiwara T; Yamanaka Y; Im D; Horita S; Tsujimoto H; Tawaramoto MS; Hirokawa T; Nango E; Tono K; Kameshima T; Hatsui T; Joti Y; Yabashi M; Shimamoto K; Yamamoto M; Rosenbaum DM; Iwata S; Shimamura T; Kobayashi T
    Structure; 2018 Jan; 26(1):7-19.e5. PubMed ID: 29225076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study.
    Karhu L; Magarkar A; Bunker A; Xhaard H
    J Phys Chem B; 2019 Mar; 123(12):2609-2622. PubMed ID: 30786708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
    Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
    Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation.
    Hong C; Byrne NJ; Zamlynny B; Tummala S; Xiao L; Shipman JM; Partridge AT; Minnick C; Breslin MJ; Rudd MT; Stachel SJ; Rada VL; Kern JC; Armacost KA; Hollingsworth SA; O'Brien JA; Hall DL; McDonald TP; Strickland C; Brooun A; Soisson SM; Hollenstein K
    Nat Commun; 2021 Feb; 12(1):815. PubMed ID: 33547286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes.
    Karhu L; Turku A; Xhaard H
    BMC Struct Biol; 2015 May; 15():9. PubMed ID: 25957175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between the Human OX2 Orexin Receptor and Suvorexant and Some of Its Analogues: SAPT (DFT) Interaction Energy Decomposition Analysis.
    Farrokhpour H; Bamdad F; Ashrafizaadeh M
    J Phys Chem B; 2022 Oct; 126(39):7528-7540. PubMed ID: 36166366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs.
    McGaughey G; Bayly CI; Cox CD; Schreier JD; Breslin MJ; Bogusky M; Pitzenberger S; Ball R; Coleman PJ
    J Comput Aided Mol Des; 2014 Jan; 28(1):5-12. PubMed ID: 24488306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis.
    Heifetz A; Morris GB; Biggin PC; Barker O; Fryatt T; Bentley J; Hallett D; Manikowski D; Pal S; Reifegerste R; Slack M; Law R
    Biochemistry; 2012 Apr; 51(15):3178-97. PubMed ID: 22448975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.
    Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H
    J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of methamphetamine on actigraphy-based sleep parameters in female rhesus monkeys: Orexin receptor mechanisms.
    Borgatti DA; Rowlett JK; Berro LF
    Drug Alcohol Depend; 2024 Jun; 259():111285. PubMed ID: 38636173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
    Cui D; Cabalu T; Yee KL; Small J; Li X; Liu B; Maciolek C; Smith S; Liu W; McCrea JB; Prueksaritanont T
    Xenobiotica; 2016 Oct; 46(10):882-95. PubMed ID: 26864332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
    Rappas M; Ali AAE; Bennett KA; Brown JD; Bucknell SJ; Congreve M; Cooke RM; Cseke G; de Graaf C; Doré AS; Errey JC; Jazayeri A; Marshall FH; Mason JS; Mould R; Patel JC; Tehan BG; Weir M; Christopher JA
    J Med Chem; 2020 Feb; 63(4):1528-1543. PubMed ID: 31860301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
    Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
    ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective synthesis of a dual orexin receptor antagonist.
    Mangion IK; Sherry BD; Yin J; Fleitz FJ
    Org Lett; 2012 Jul; 14(13):3458-61. PubMed ID: 22725839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galaxy7TM: flexible GPCR-ligand docking by structure refinement.
    Lee GR; Seok C
    Nucleic Acids Res; 2016 Jul; 44(W1):W502-6. PubMed ID: 27131365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells.
    Kukkonen JP
    Cell Signal; 2016 Feb; 28(2):51-60. PubMed ID: 26582739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.